(Q37904672)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

review article

1 reference

title

Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

H R Ashbee

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

25 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

881-894

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bmt.2011.146

8 February 2020

exact match

0 references

cites work

Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Genetic variants of human serum albumin in Italy: point mutants and a carboxyl-terminal variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Genetic variation in drug transporters in ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Cytochrome p450 and chemical toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

CYP2C9 allelic variants: ethnic distribution and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

CYP3A5 phenotype-genotype correlations in a British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacogenetics of the major polymorphic metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The lipid formulations of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Antifungals: mechanism of action and resistance, established and novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Increased gastric pH and the bioavailability of fluconazole and ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Fluconazole penetration in cerebral parenchyma in humans at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Cyclophosphamide metabolism is affected by azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Optimisation of itraconazole therapy using target drug concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Role of itraconazole metabolites in CYP3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Voriconazole concentrations and outcome of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetic/pharmacodynamic profile of posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

A pharmacogenetics study of the human glucuronosyltransferase UGT1A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Hepatic uptake of the novel antifungal agent caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Potential for interactions between caspofungin and nelfinavir or rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Micafungin: a new echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Micafungin: pharmacology, experimental therapeutics and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Echinocandins: the newest class of antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Antifungal serum concentration monitoring: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Therapeutic drug monitoring of voriconazole and posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Posaconazole therapeutic drug monitoring: a reference laboratory experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Next-generation DNA sequencing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Fasting gastric pH and its relationship to true hypochlorhydria in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Alterations in gastric acidity in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Drug uptake systems in liver and kidney: a historic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Drug metabolism and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The human intestinal cytochrome P450 "pie".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Gene expression and regulation of drug transporters in the intestine and kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Impact of OATP transporters on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The complexities of hepatic drug transport: current knowledge and emerging concepts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Mechanisms of renal anionic drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

P-glycoprotein: from genomics to mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Genetic polymorphisms of the human MDR1 drug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Aerosolized Delivery of Antifungal Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Interaction of common azole antifungals with P glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Interaction of cytochrome P450 3A inhibitors with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Does inhibition of P-glycoprotein lead to drug-drug interactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Clinical Pharmacokinetics of Atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Severe vincristine toxicity in combination with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Concomitant use of voriconazole and rifabutin in a patient with multiple infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Development and validation of a quantitative assay based on tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Treatment of invasive aspergillosis with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Itraconazole therapy for cryptococcal meningitis and cryptococcosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

Pharmacology of Systemic Antifungal Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

The promises of personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Nutritional and metabolic support in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Albumin genetic variability in South America: Population distribution and molecular studies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Interaction of plasma proteins and lipoproteins with amphotericin B

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Voriconazole and multidrug resistance in Candida albicans

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Identification of 12 novel mutations and two new polymorphisms in the arylsulfatase A gene: haplotype and genotype-phenotype correlation studies in Spanish metachromatic leukodystrophy patients.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Effect of omeprazole on the pharmacokinetics of itraconazole

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Bioinformatics research on inter-racial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.146

7 January 2021

Identifiers

DOI

10.1038/BMT.2011.146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785468%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference